Lycia Therapeutics, a clinical-stage biotechnology company developing protein-degrading therapies for allergic and autoimmune diseases, has announced terms for a proposed $250 million initial public offering (IPO). The South San Francisco-based company plans to offer 14.7 million shares at $16 to $18 each, implying a fully diluted market value of approximately $950 million at the midpoint of the proposed range.

Company Background

Founded in 2019, Lycia Therapeutics is developing treatments designed to degrade disease-causing extracellular proteins, with an initial focus on autoimmune, inflammatory, and allergic diseases. Its technology platform, known as Lysosomal Targeting Chimera (LYTAC), is based on research by Nobel laureate Carolyn Bertozzi at Stanford University.

The company’s approach is intended to target extracellular proteins associated with disease. Its development pipeline includes candidates for food allergy and Graves’ disease, with programs at different stages of clinical and preclinical development.

IPO Details

Lycia Therapeutics plans to raise $250 million through the proposed offering of 14.7 million shares at a price range of $16 to $18 per share. At the midpoint, the company would have a fully diluted market value of approximately $950 million.

The company intends to list on the Nasdaq under the ticker symbol LYCA. Jefferies, TD Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital are serving as joint bookrunners. The offering was expected to price during the week of October 19, 2026.

Lycia reported $4 million in revenue for the 12 months ended June 30, 2026. The available information does not specify the source of that revenue or provide a complete picture of the company’s operating expenses, cash position, or funding requirements.

Pipeline and Clinical Development

Lycia’s lead candidate, LCA-0061, is designed to degrade immunoglobulin E (IgE), an antibody associated with allergic diseases, including food allergy. The candidate is being evaluated in a Phase 1 trial.

Preliminary results from the first cohort included eight healthy atopic participants, two of whom received placebo. Among participants who received the treatment, the company reported a mean maximum reduction in IgE of 96% from baseline. These preliminary findings represent an early clinical signal and do not establish the candidate’s long-term safety, efficacy, or ability to treat food allergies.

A second IgE-targeting candidate, LCA-0062, remains in investigational new drug (IND)-enabling activities. Lycia is also conducting a Phase 1 trial of LCA-0321, which is designed to selectively degrade the autoantibodies that drive Graves’ disease.

The pipeline provides the company with several development programs, but each remains subject to the clinical testing and regulatory process required before a potential treatment can reach the market.

Market Context and Opportunities

Lycia’s proposed listing would provide public-market financing for a biotechnology business focused on extracellular protein degradation. The company’s LYTAC platform and early clinical data are central elements of its development strategy, while its programs address allergic and autoimmune conditions.

The proposed valuation of approximately $950 million at the midpoint reflects the market value contemplated by the offering terms. The available source does not provide enough information to determine how that valuation compares with the company’s future financing needs or the commercial potential of individual pipeline candidates.

Risks and Challenges

Lycia’s principal development risk is the early stage of its clinical programs. Preliminary biomarker changes, including the reported IgE reduction, do not by themselves demonstrate a clinically meaningful benefit for patients. Further trials will be needed to assess safety, durability, and therapeutic outcomes.

The company also faces the funding demands associated with advancing multiple drug candidates. Its reported $4 million in revenue provides limited information about its ability to finance continued research and development without additional capital. The proposed IPO could provide funding, but the ultimate proceeds and valuation would depend on the final offering terms and completion of the transaction.

Closing Insights

Lycia Therapeutics’ proposed $250 million IPO would bring a clinical-stage biotechnology company focused on protein degradation to the public markets. Its early IgE findings and pipeline targeting food allergy and Graves’ disease are key elements of its investment profile, but the programs remain in early development. Investors evaluating the offering will need to weigh the platform’s potential against clinical uncertainty, financing requirements, and the time needed to establish therapeutic value.